Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 21.4% in February

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,980,000 shares, a decline of 21.4% from the February 13th total of 2,520,000 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average daily volume of 5,940,000 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC acquired a new position in Cardio Diagnostics in the fourth quarter valued at approximately $48,000. Jane Street Group LLC acquired a new position in Cardio Diagnostics in the fourth quarter valued at approximately $103,000. Millennium Management LLC acquired a new position in Cardio Diagnostics in the fourth quarter valued at approximately $236,000. Finally, Geode Capital Management LLC lifted its holdings in Cardio Diagnostics by 97.6% in the fourth quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock valued at $334,000 after acquiring an additional 179,978 shares during the last quarter. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Cardio Diagnostics Trading Up 2.7 %

CDIO traded up $0.01 during trading hours on Wednesday, reaching $0.45. The company’s stock had a trading volume of 260,520 shares, compared to its average volume of 2,510,981. Cardio Diagnostics has a fifty-two week low of $0.19 and a fifty-two week high of $1.77. The business’s 50-day moving average is $0.51 and its 200-day moving average is $0.47.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.